Compare Archer-Daniels-Midland Co (ADM) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Amylx Pharmaceuticals Inc — how do they compare? Archer-Daniels-Midland Co trades at $79.83 (market cap $37.69B), while Amylx Pharmaceuticals Inc trades at $17.82 (market cap $2.02B). The key difference: Archer-Daniels-Midland Co is far larger — about 18.7× Amylx Pharmaceuticals Inc's market cap, and Archer-Daniels-Midland Co pays a 2.66% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ADM | AMLX | |
|---|---|---|
Market Cap | $37.69B | $2.02B |
Sector | Consumer Staples | Health |
52-Week High | $84.11 | $18.70 |
52-Week Low | $53.54 | $6.98 |
Enterprise Value | $47.72B | $1.75B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $78.20, up 1.84% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $78.00. The company has beaten EPS estimates for three consecutive quarters, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Net cash flow improved to $1.58B in 2025, reversing negative trends from prior years, while the stock shows a P/E of 34.79 and P/S of 0.47, indicating mixed valuation signals.
Outlook is cautiously optimistic with strong cash flow and earnings beats, but risks include declining revenue margins and competitive pressures. The stock offers value characteristics with a low P/S ratio, yet investors face headwinds from narrowing profit margins and global trade volatility in agricultural markets.
AMLX trades at $17.97, down 1.64% today, with strong analyst support showing 91% buy ratings and a $30.50 consensus price target representing 70% upside potential. The stock shows bullish technical momentum with positive moving average signals, though RSI levels suggest some overbought conditions. Recent earnings showed mixed results with a Q1 2026 miss after two previous beats, while the company continues advancing its pipeline with Phase 3 data for avexitide expected in Q3 2026.
Despite negative profitability metrics and cash burn, AMLX maintains strong institutional confidence with 11 analysts covering the stock. The key catalyst remains the upcoming Phase 3 avexitide readout, though risks include ongoing class action litigation and the company's negative cash flow from operations. Current valuation at 7.31x book value reflects optimism around pipeline assets rather than current financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
